Supplementary Figure S4 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer
<p>Supplementary Figure S4: A-B, MDA-MB-231 (A), and BT-549 (B), cells were treated with HBS-101, stained with Annexin V, and analyzed by flow cytometry. Scatter plots illustrate Annexin V staining in control and HBS-101-treated cells.</p>
Authors
- Dong Liang (ORCID: https://orcid.org/0000-0001-6632-8066)
- Hareesh B. Nair
- Megharani Mahajan (ORCID: https://orcid.org/0000-0002-6259-5754)
- Huan Xie (ORCID: https://orcid.org/0000-0002-0591-5619)
- John R. Sanchez (ORCID: https://orcid.org/0000-0002-5362-1025)
- Jessica D. Johnson (ORCID: https://orcid.org/0000-0002-5331-7461)
- Sridharan Jayamohan (ORCID: https://orcid.org/0000-0002-8430-0881)
- Yang Wang (ORCID: https://orcid.org/0000-0002-0429-9412)
- Suryavathi Viswanadhapalli
- Manjeet K. Rao (ORCID: https://orcid.org/0000-0001-7573-2677)
- Gangadhara R. Sareddy (ORCID: https://orcid.org/0000-0001-9977-3932)
- Panneerdoss Subbarayalu (ORCID: https://orcid.org/0000-0002-9028-7193)
- K.V. Dileep (ORCID: https://orcid.org/0000-0002-7456-4226)
- Ratna K. Vadlamudi (ORCID: https://orcid.org/0000-0003-2849-4076)
- Alondra L. Rodriguez Sanchez
Publication Details
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1158/1535-7163.30028855
- Primary Topic
- Glycosylation and Glycoproteins Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00